Why Do Scleroderma Fingers Change From Puffy to Tight?
At a Glance
It is completely normal for scleroderma skin to change from puffy and swollen to tight, hard, and eventually thin. This transition reflects the natural three-phase progression of the disease—the edematous, fibrotic, and atrophic phases—rather than a sign that your treatment has failed.
In this answer
2 sections
Yes, this transition is entirely normal and expected. Going from fingers that are puffy and swollen to skin that feels tight, hard, and eventually thin is the classic, natural trajectory of scleroderma skin changes [1]. When your symptoms change drastically, it is easy to worry that your condition is rapidly worsening or that your medications have stopped working. However, this shift usually reflects the natural physiological evolution of the disease rather than a treatment failure [2]. Even so, you should always report significant symptom shifts to your rheumatologist so they can appropriately track your progression and adjust your care [3].
Understanding the Three Phases of Scleroderma Skin Changes
Scleroderma skin involvement typically progresses through three distinct, sometimes overlapping phases [1]. The speed and extent of these changes can vary significantly depending on whether you have limited or diffuse cutaneous systemic sclerosis [4].
-
The “Puffy” Phase (Edematous Phase): This is the earliest stage, characterized by swollen, puffy fingers [5]. Early damage to the small blood vessels causes them to become “leaky,” allowing fluid to build up in the surrounding tissues [6]. This creates localized inflammation and swelling, which is often accompanied by extreme itchiness [6][5].
-
The “Tight” Phase (Fibrotic or Indurative Phase): As the initial fluid buildup subsides, the body’s immune system mistakenly signals cells to overproduce collagen, a structural protein that acts like tough scar tissue [7]. This excess collagen builds up, causing the skin to become progressively thicker, harder, and tighter [8][7]. During this stage—which often peaks in the first few years of the disease—the skin loses its flexibility, making it harder to fully bend or straighten your fingers [9]. Your care team may recommend intensive moisturizing and daily hand stretching exercises during this window to help preserve your range of motion [10].
-
The “Thin” Phase (Atrophic Phase): Over months or years, the aggressive collagen production tends to slow down, and the thick skin may actually begin to soften [2][11]. However, this late stage is marked by tissue atrophy (wasting away), meaning the skin becomes fragile, thin, and shiny [1][12]. Because the skin often remains stretched tightly over the underlying bones and joints—a condition known as sclerodactyly—it can feel both tight and thin at the same time [7]. You may also notice a loss of hair, reduced sweating, and a decrease in the supportive layer of subcutaneous fat beneath the skin in these areas [12][13].
Why the Distinction Matters
Because your skin is transitioning from an active inflammatory phase to a structural fibrotic or atrophic phase, the way your symptoms look and feel will naturally change over time [14].
Doctors track these changes using the Modified Rodnan Skin Score (mRSS), a standardized clinical exam where a doctor pinches the skin across different areas of your body to measure its thickness [3]. Recognizing where you are in this three-phase process helps your medical team evaluate the natural timeline of your condition and understand which physical changes are expected [3][15].
For instance, while thin and tightly stretched skin on the fingers is part of the normal late-stage trajectory, it is significantly more fragile. This makes it highly prone to complications like digital ulcers (painful sores on the fingertips) [10]. To help prevent these complications, your doctor may recommend proactive skin protection strategies, such as:
- Keeping your hands warm at all times
- Wearing protective gloves during chores
- Frequently applying thick barrier creams
- Avoiding minor trauma or cuts to the fingers
Understanding your current phase allows you and your care team to shift focus from managing acute swelling to protecting your skin’s long-term integrity.
Common questions in this guide
Is it normal for my scleroderma swelling to turn into tight skin?
What is the Modified Rodnan Skin Score (mRSS)?
How can I protect my fingers during the thin skin phase of scleroderma?
Can hand exercises help with tight skin from scleroderma?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Based on my current physical examination, which phase of scleroderma skin changes am I primarily in?
- 2.What is my current Modified Rodnan Skin Score (mRSS), and how has it changed compared to my previous visits?
- 3.Now that my skin is thinning and feeling tight, what specific barrier creams or protective gloves do you recommend to prevent digital ulcers?
- 4.Are there specific hand stretching exercises or occupational therapy routines I should be doing to preserve my finger mobility?
- 5.Does my transition from puffy to tight and thin skin mean we should re-evaluate or adjust my current systemic medications?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (15)
- 1
Sclerosing diseases of the skin.
Kalantari Y, Meier K, Ghoreschi K, et al.
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2025; (23(10)):1282-1300 doi:10.1111/ddg.15835.
PMID: 41030177 - 2
Skin involvement in early diffuse cutaneous systemic sclerosis: an unmet clinical need.
Herrick AL, Assassi S, Denton CP
Nature reviews. Rheumatology 2022; (18(5)):276-285 doi:10.1038/s41584-022-00765-9.
PMID: 35292731 - 3
Assessment of skin disease in scleroderma: Practices and opinions of investigators studying scleroderma.
Showalter K, Merkel PA, Khanna D, Gordon JK
Journal of scleroderma and related disorders 2020; (5(3)):167-171 doi:10.1177/2397198320921044.
PMID: 35382518 - 4
Cutaneous Manifestations, Clinical Characteristics, and Prognosis of Patients With Systemic Sclerosis Sine Scleroderma: Data From the International EUSTAR Database.
Lescoat A, Huang S, Carreira PE, et al.
JAMA dermatology 2023; (159(8)):837-847 doi:10.1001/jamadermatol.2023.1729.
PMID: 37378994 - 5
Self-Reported Systemic Sclerosis-Related Symptoms Are More Prevalent in Subjects with Raynaud's Phenomenon in the Lifelines Population: Focus on Pulmonary Complications.
van de Zande SC, Abdulle AE, Al-Adwi Y, et al.
Diagnostics (Basel, Switzerland) 2023; (13(13)) doi:10.3390/diagnostics13132160.
PMID: 37443554 - 6
Vascular Leaking, a Pivotal and Early Pathogenetic Event in Systemic Sclerosis: Should the Door Be Closed?
Bruni C, Frech T, Manetti M, et al.
Frontiers in immunology 2018; (9()):2045 doi:10.3389/fimmu.2018.02045.
PMID: 30245695 - 7
Frontiers in translational systemic sclerosis research: A focus on the unmet 'cutaneous' clinical needs (Viewpoint).
Herrick AL, Shukla R, Watson REB
Experimental dermatology 2020; (29(12)):1144-1153 doi:10.1111/exd.14179.
PMID: 32840924 - 8
Connective Tissue Diseases in the Skin: Emerging Concepts and Updates on Molecular and Immune Drivers of Disease.
Bitar C, Chan MP
Surgical pathology clinics 2021; (14(2)):237-249 doi:10.1016/j.path.2021.03.003.
PMID: 34023103 - 9
A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis.
Allanore Y, Wung P, Soubrane C, et al.
Annals of the rheumatic diseases 2020; (79(12)):1600-1607 doi:10.1136/annrheumdis-2020-218447.
PMID: 32963047 - 10
Malnutrition, associated clinical factors, and depression in systemic sclerosis: a cross-sectional study.
Türk İ, Cüzdan N, Çiftçi V, et al.
Clinical rheumatology 2020; (39(1)):57-67 doi:10.1007/s10067-019-04598-y.
PMID: 31129793 - 11
Prediction of improvement in skin fibrosis in diffuse cutaneous systemic sclerosis: a EUSTAR analysis.
Dobrota R, Maurer B, Graf N, et al.
Annals of the rheumatic diseases 2016; (75(10)):1743-8 doi:10.1136/annrheumdis-2015-208024.
PMID: 27016052 - 12
Systemic sclerosis and scleroderma renal crisis in African American patients.
Kotamarti R, Hackshaw KV
Journal of the National Medical Association 2025; (117(3)):179-184 doi:10.1016/j.jnma.2025.04.006.
PMID: 40368669 - 13
Prediction of disease relapse in a cohort of paediatric patients with localized scleroderma.
Kurzinski KL, Zigler CK, Torok KS
The British journal of dermatology 2019; (180(5)):1183-1189 doi:10.1111/bjd.17312.
PMID: 30315656 - 14
High-content Image-based Drug Testing of Patients' Primary Fibroblasts Reveals Potential New Treatment Options for Localized Scleroderma.
Mähönen K, Mogollon I, Hassinen A, et al.
Acta dermato-venereologica 2025; (105()):adv43088 doi:10.2340/actadv.v105.43088.
PMID: 40753487 - 15
Existing and novel biomarkers for precision medicine in systemic sclerosis.
Wermuth PJ, Piera-Velazquez S, Rosenbloom J, Jimenez SA
Nature reviews. Rheumatology 2018; (14(7)):421-432 doi:10.1038/s41584-018-0021-9.
PMID: 29789665
This page explains the natural progression of scleroderma skin changes for educational purposes. It does not replace professional medical advice; always consult your rheumatologist about your specific symptoms and symptom changes.
Get notified when new evidence is published on Scleroderma.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.